Challenges in interpreting comprehensive biomarker testing and a few paths to address them

Addressing cancer disparities in Hispanic populations in the US and in low and middle income countries

Updates on triple-negative breast cancer and immunotherapy

Liquid biopsies and cancer: The role of NGS, CTC, exosomes, cfDNA and cfRNA

Predictive and prognostic biomarkers for immunotherapy in lung cancer

Updates in melanoma and skin cancers

Gynaecological cancer: New targets and immunotherapy developments

Molecular oncology and translational medicine

Immunotherapy in NSCLC: Adjuvant and neoadjuvant clinical scenarios

Adjuvant nivolumab vs placebo in resected oesophageal or gastroesophageal junction cancer following chemo: Biomarker analysis

Addressing cancer disparities in Hispanic populations in the US and in LMICs

Potential benefit to response rates from trastuzumab added to perioperative chemotherapy for patients with HER-2+ GC